References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism.

Slides:

Advertisements

Similar presentations

Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.

Advertisements

Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.

VTE Prophylaxis in the Hospitalized Patient: Importance and Strategies for Improved Compliance Andrew H. Dombro, M.D. Instructor of Medicine Division of.

Fundamental Research in Oncology and Thrombosis Cancer and thrombosis – a complex relationship lCancer may increase the risk of thrombosis through multiple.

Consensus Statements and Guidelines on Antithrombotic Therapy  VTE is a major health problem, particularly among the elderly. VTE  Symptoms :non-specific,

Venous thromboembolism: how long to treat?

WHAT YOU NEED TO KNOW ABOUT BLOOD CLOTS VTE Venous Thromboembolism Toolkit for Health Professionals.

Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

Cancer-Associated Thrombosis

The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.

Critical Appraisal Athar Yasin EOE - RTD Jan 2012.

Risk Assessment for VTE. Which of the following best describes you?

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.

Chapter 9: Vascular Complications of Cancer and Cancer Treatment

Extended Treatment of VTE in Cancer Patients

CRT 2012 Venous Disease.

Venous Thromboembolism Prophylaxis for Medical Inpatients

Clinical Professor in Palliative Medicine

Venous Thromboembolism Prophylaxis (VTE)

Evaluating The Accuracy Of International Classification Of Diseases 10TH Revision Codes For Venous Thromboembolism (VTE) And Major Bleeding (MB) in.

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Copyright © 2003 American Medical Association. All rights reserved.

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

D-dimer and helical CT-PA based diagnostic algorithm for PE

Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon

Copyright © 2012 American Medical Association. All rights reserved.

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Outpatient Venous Thromboembolism Prophylaxis in Lower Limb Injuries:

The heart and science of medicine.

Extended Treatment of VTE: Who is the Right Candidate?

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

New Oral Anticoagulants and VTE Management

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Succinct Review of the New VTE Prevention and Management Guidelines

Extraordinary Cases of VTE Prevention in Patients With Cancer

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Flow chart of the used methodology adapted from Moher et al

References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Disease Burden of VTE Phases of VTE Treatment.

Algorithm for the outpatient management of pulmonary embolism (PE)

QUALITY: SAFE CARE Potentially Preventable Adverse Events and Complications of Care in Hospitals Among Medicare Beneficiaries, 2004–2005 Percent *Surgical.

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Presentation transcript:

References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007 Mar 1;5(3):632-4. 2. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291. 3. Heit JA. Cancer Control 2005;12(Suppl 1):5–10. 4. Lipp R, Feuerbach M, Freigang F et al. Economic burden of cancer associated thrombosis in Germany - Findings and extrapolations (1037P). European Society of Medical Oncology. Copenhagen, Denmark, 2016. 5. Prandoni P. The Treatment of Venous Thromboembolism in Patients with Cancer. Adv Exp Med Biol - Advances in Internal Medicine (2017) 1: 123-135. 6. Prandoni P, Lensing AW, Piccioli A, et al. Blood. 2002 Nov 15;100(10):3484-8. Active Cancer: 1. National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing 2012; NICE guideline CG144. Thrombosis together with infections is the second-leading cause of death in cancer patients: 2. Trujillo-Santos J, Martos FM, Font C, et al. Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon. 2017 Jan 1;3(1):e00229. 3. Cancer-Associated Thrombosis (CAT ), a neglected cause of Cancer Death: actions needed to increase health outcomes and reduce mortality. Report summarising the findings of an Expert Steering Group meeting in Belgium. Most frequent causes of death in patients initially presenting with PE: 1. Trujillo-Santos J, Martos FM, Font C et al. Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Heliyon 2017 Jan 1;3(1):e00229.

References: How does advanced cancer affect CAT treatment outcomes? 1. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291. 2. Diez de los Rios de la Serna C, Richardson A, Lennan E (2017) Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE. Cancer Nursing Practice. 16, 4, 21-26. Date of submission: 17 November 2016; date of acceptance: 10 March 2017. Survival rate is lower when cancer patients also experience VTE: Cancer biology: Extrinsic factors 1. Heit JA. Cancer Control 2005;12(Suppl 1):5–10. 2. Young A, Chapman O, Connor C, et al. Thrombosis and cancer. Nature reviews Clinical oncology. 2012 Aug;9(8):437. What is the added cost of CAT per patient, on top of cancer? 1. Lipp R, Feuerbach M, Freigang F, et al. Economic burden of cancer associated thrombosis in Germany - Findings and extrapolations (1037P). European Society of Medical Oncology. Copenhagen, Denmark, 2016 VTE adds complexity to cancer patient management 1. P. Prandoni. The Treatment of Venous Thromboembolism in Patients with Cancer. Adv Exp Med Biol - Advances in Internal Medicine (2017) 1: 123–135 2. Voigtlaender M, Langer F. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. Hämostaseologie 2017; 37: 241-55 CAT management is different from classic VTE management 1. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002 Nov 15;100(10):3484-8.